Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NIB in 2023: Strong earnings with high impact

The Nordic Investment Bank (NIB) maintained a strong level of lending disbursements at EUR 3,446 million (EUR 3,705 million in 2022). Continued demand enabled NIB to prioritise high impact and additionality. A large share of disbursements went to the energy sector facilitating decarbonisation in NIB’s member countries. Another key area was research and development. “NIB delivered strong earnings and impact in 2023. During the year, we achieved significant milestones such as the opening of a new office in Riga, published our Climate Strategy, and continued to develop our product offering,

SRV Group Plc’s Annual Report 2023 published

SRV GROUP PLC     ANNUAL FINANCIAL REPORT     29 FEBRUARY 2024      10:00 EETSRV Group Plc’s Annual Report 2023 publishedSRV Group Plc’s Annual Report 2023 has been published today on 29 February 2024 on www.srv.fi/en/investors . SRV’s Annual Report 2023 contains the Report of the Board of Directors, Financial Statements, Corporate Governance Statement, Remuneration Report, sustainability appendix and Corporate Sustainability Report 2023. In its 2023 Annual Report, SRV will be reporting on

Cereno Scientific reports one new patient enrolled, one additional patient randomized, and one additional patient completed in the Phase II Study of CS1 in PAH

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that one new additional patient have been enrolled in the study, one additional patient has been randomized on CS1 drug and one additional patient has completed the study. This update serves as the latest progress update for the Phase II study of drug candidate CS1 in rare disease pulmonary arterial hypertension (PAH). The study is set to be completed by Q3 2024.The Phase II study of CS1 in the rare disease PAH is actively running at 10

Biosergen publishes interim report for fourth quarter 2023

Thursday, February 29, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the fourth quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)Summary of the Interim Report for Q4 2023 2023 2022 2023 2022TSEK Oct-Dec Oct-Dec Jan-Dec Jan-Dec Other income 1.315 1.964 9.378 5.183Profit/loss before depreciation (EBITDA) -6.662 -12.491 -27.266

RIGHTBRIDGE VENTURES GROUP YEAR END REPORT 2023

THE RESTRUCTURING OF THE PORTFOLIO IS NOW COMPLETED – RIGHTBRIDGE IS POISED FOR NEW OPPORTUNITIESProfit and loss, in Oct-Dec Jan-Decsummary, groupSEK thousands 2023 2022 2023 2022Revenue 1.029 2.980 6.802 8.445EBITDA -2.858 -17.225 -14.579 -23.598Adjusted EBITDA -1.858 -5.846 -9.205 -12.219Depreciation, -951 -53.198 -27.350 -54.208amortization andimpairment lossesEarnings Before Interest -3.822 -70.426 -41.945 -77.828and Taxes (EBIT)

Reltime expands its Revolutionary Web3 Platform with four new services and user identity at its core

Oslo - Norway, 29th February 2024:  Reltime has once again positioned itself at the forefront of innovation in the next-generation digital and financial services industry by being the first to integrate four fundamental elements into its Web3 platform: Streaming and Interactions, Identity and Rewards, the fastest Decentralized Exchange (DEX) and Wallet, and Gaming in the Metaverse. This holistic integration represents a monumental leap forward in blockchain-enabled applications, emphasising user engagement, security, and an immersive experience. [Reltime expands its Revolutionary Web3

Beijer Ref acquires Quality Air Equipment in Australia

Beijer Ref has signed an agreement to acquire 60 per cent of the shares in Quality Air Equipment (QAE), with an option to acquire the remaining shares. QAE is a manufacturer and distributor of HVAC components and accessories. The company has an annual turnover of approximately SEK 140 million. Founded in 2000, QAE is headquartered in Sydney (Australia). The company will continue to operate under its own brand and existing management will continue to develop the business together with Beijer Ref. The acquisition is in line with Beijer Ref's overall acquisition strategy and strengthens

Interim Report Scandinavian Enviro Systems AB (publ) January – December 2023

Intensive and exhaustive work laid the basis for the final investment decision.Q4 2023 · Net revenues for the period were MSEK 3.2 (2.0) · Earnings after tax for the period were MSEK -23.6 (-25.0) · Earnings per share for the period (before dilution) was SEK -0.03 (-0.04) · Cash flow for the period after investments was MSEK -28.4 (-26.2) · Enviro has developed new type of recovered carbon black with improved properties · Enviro wins prestigious award at the Recircle Awards – third year in a row Period of January-December 2023 · Net revenues for the period were

Freetrailer Group presents quarterly report Q2 2023-2024

The second quarter of Freetrailer's financial year 23/24 shows an increase in revenue of 42.4%. The number of rentals reached a new record of 272,441, corresponding to an increase of 34.6%. The quarterly results support a significant upward revision of the company's expectations for the year's overall performance.Increased expectations for rentals 23/24 Momentum from the first 6 months of the year has led the company to raise its full-year rental guidance from 1,135,000 to 1,180,000. The increased guidance reflects an expected 30% growth in the number of rentals compared to the total

NOTICE OF ANNUAL GENERAL MEETING IN NAXS AB (publ)

Not for release, publication or distribution, directly or indirectly, in or into the United States, Hong Kong, Canada, Japan or Australia, or any other jurisdiction in which the distribution or release would be unlawful. N.B. The English text is an in-house translation. In the event of any discrepancies between the text in this document and the Swedish document, the latter shall prevail. The shareholders of NAXS AB (publ), reg. no. 556712-2972, with its registered office in Stockholm (the “Company” or “NAXS”), are hereby invited to the annual general meeting (the “Meeting”) on

Scandic Nürnberg Central to open its doors

Tomorrow marks the opening of Scandic’s first hotel in Nürnberg, the second largest metropolitan area in Bavaria. The new hotel is an important step in the company’s expansion in Germany. With 311 rooms and event facilities for up to 800 people, the newly renovated hotel has been rebranded as a Scandic hotel since it was taken over from Pandox. Scandic Nürnberg Central will be operated by Scandic pursuant to a long-term revenue-based lease agreement from March 1, 2024.Scandic Nürnberg Central is located in the heart of the city, just a few minutes’ walk from the historic district and

Sensys Gatso’s partner signs contract for traffic safety solution in Finland, worth estimated SEK 20 million

Sensys Gatso Group, a global leader in traffic safety solutions, has through its partner Destia Oy, signed a contract with the procuring organisations Fintraffic and The National Police board of Finland for the delivery of traffic-safety cameras in Finland. Sensys Gatso’s part for the delivery of traffic-safety cameras under the procurement award, is estimated to be worth SEK 20 million, over the 4 year contract period.The award of the procurement was announced January 12. Sensys Gatso’s partner Destia OY has now signed the contract with the procuring organisations Fintraffic and The

Gaming Innovation Group – Exercise of options and mandatory notification of trade

Justin Psaila, CFO and primary insider of Gaming Innovation Group Inc. (GiG), has today exercised his options to buy 45,000 shares in GiG, whereof 30,000 at a share price of NOK 15.00 and 15,000 at a share price of NOK 22.00. After this transaction, Justin Psaila will own 47,100 shares and 15,000 options in GiG. Claudio Caruana, General Counsel and primary insider of Gaming Innovation Group Inc. (GiG), has today exercised his options to buy 30,000 shares in GiG at a price of NOK 15.00 per share. After this transaction, Claudio Caruana will own 30,100 shares and 30,000 options in GiG.

Nordea cancels repurchased shares

Nordea Bank AbpStock exchange release – Total number of voting rights and capital29 February 2024 at 9.15 EET Nordea has today cancelled 15,912,565 treasury shares in line with the decision by the Board of Directors. The shares were held for capital optimisation purposes and acquired through share buy-backs. The cancellation brings the total number of shares in Nordea to 3,505,587,395. The total number of votes attached to the shares is 3,505,587,395. The cancellation of the shares was registered with the Finnish Trade Register on 29 February 2024. The company holds 4,787,

Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and its partner Eisai will present new data on lecanemab (brand name: Leqembi®) at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), to be held in Lisbon, Portugal and virtually, March 5-9. In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic’s founder Professor Lars Lannfelt.Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and

From anonymity to recognition: The challenge of underdiagnosis and misdiagnosis in rare diseases

As we highlight Rare Disease Day, it’s crucial to focus on the often-overlooked issue of underdiagnosis and misdiagnosis in conditions like Arginase 1 Deficiency (ARG1-D), a progressive genetic metabolic disorder characterized by elevated plasma arginine levels, leading to serious health issues. ARG1-D presents with progressive neurological impairment, developmental delay, progressive spasticity and intellectual disability. The invisibility of rare diseases like ARG1-D in both public awareness and medical practice results in delayed interventions or even the omission of relevant treatments,

Fazer Group’s Annual Review 2023 published

Fazer’s Annual Review, Financial Review and Corporate Governance Report have been published today. These reports provide a comprehensive overview of the company's business and sustainability performance, and governance practices in 2023.Despite encountering a challenging market in 2023, Fazer's operational performance was good, and the demand for the products remained high throughout the year. Fazer’s Annual Review gives an in-depth look into Fazer’s year in 2023 and the path forward as a Food Experience Company. The Annual Review is available in Finnish, Swedish, and English and

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In February, at the request of shareholders, 6,410 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,251,072,876. The total number of registered shares in the company amounts to 702,342,489 of which 60,970,043 are Class

Q4 2023 Interim financial report

FINANCIAL HIGHLIGHTS· Group revenue of SEK 222.4m (SEK 235.0m). · Gross profit margin 44.7% (40.7%). · EBITDA of SEK 27.0m (SEK 23.2m). · Net operating cash flow SEK 28.6m (SEK 27.5m). · Sale of vacuum business, Sibilia Nordic. · New cooperation with supplier of smart lockers. · The Company has engaged Arctic Securities and Pareto Securities to explore refinancing options for the outstanding SEK 285m senior secured bond issue maturing 5 May 2024 (ISIN SE0015938493). · Order intake was SEK 188.5m (SEK 241.9m), and order backlog of SEK 130.3m (SEK 146.6m).

Optomed Annual Report 2023 published

Optomed Plc Stock Exchange Release 29  February 2024 at 9.00, Helsinki Optomed Annual Report 2023 published Optomed's Annual Report 2023 has been published. The Annual Report includes the company's consolidated and parent company financial statements, the report of the board of directors, the auditor’s report, corporate governance statement and remuneration report for governing bodies.   Optomed's Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements. KPMG Oy Ab, authorised public accountants, has provided an

Q4 and full year report January – December 2023

Change in executive leadership and solid cash positionHighlights fourth quarter 2023 · Cash at the end of December 2023 was EUR 20.7m (52.3 at December 2022) · Gross ERC at the end of December 2023 was EUR 280m (283 at December 2022) · Gross collections amounted to EUR 16.4m (16.4)* · Net collections amounted to EUR 14.3m (14.2)* · Cash EBITDA amounted to EUR 9.5m (10.2)* · Acquired E-Kancelaria, a Polish loan servicing and debt collection company, through its 75% owned subsidiary AxFina Highlights full year 2023 · Gross collections amounted to EUR 55.9m (70.8)*

There are no items matching the current filter
There are no more items matching the current filter
Back to top